Navigation Links
Azixa in Medical News

EpiCept Corporation Announces Pricing of Public Offering

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...tions, unknown risks or uncertainties or other risk factors. EPCT-GEN * azixa is a registered trademark of Myriad Genetics, Inc. ...

EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology

...e regulatory approval or achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...tions, unknown risks or uncertainties or other risk factors. EPCT-GEN * azixa is a registered trademark of Myriad Genetics, Inc. ...

EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that EpiCept will not receive any significant payments under ...

EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results

... had initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...d to the brain. Two additional Phase II trials for azixa are also underway in Glioblastoma multiforme and i...of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve si...

EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007

...e, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...urate assumptions, unknown risks or uncertainties or other risk factors. * azixa is a registered trademark of Myriad Genetics, Inc. EPCT-GEN ...

EpiCept Corporation to Present at the 2007 BIO InvestorForum

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Accelerates Development of Phase I Clinical Study for Cancer

...n metastases due to melanoma. EpiCept's licensing agreement with Myriad for azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of azixa continues to progress successfully.
Azixa in Medical Technology

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation today announced the results of scientific studies that (1) demonstrate that Azixa(TM) (MPC-6827) is effective in treating multiple types of human tumors in animal models, (2) rev...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Regulatory Progress on Ceplene(TM)

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... has initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...these patients. Two additional Phase II trials for azixa are underway in primary brain cancer and melanoma ...f Executive Officer. "We believe that the study of azixa in this new indication affords EpiCept with an exp...

Myriad Genetics Presents Azixa's Mode of Action at AACR

... azixa Shows Dual Activity as Vascular Disrupting Agent a...ncer Research (AACR) in Los Angeles, California. azixa has been previously shown to be an inducer of apop...nd subsequent tumor cell death. In recent studies, azixa induced cell death in several primary types of end...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

...ubsequent tumor cell death. Myriad reported that azixa induced cell death in several primary types of a t... human ovarian cancer xenografts, a single dose of azixa induced dramatic tumor blood vessel damage and tum...ation of the substantial clinical opportunity that azixa represents," remarked Jack Talley, President and C...

EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting

...y cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...
Azixa in Biological Technology

EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference

...plene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... has initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...these patients. Two additional Phase II trials for azixa are underway in primary brain cancer and melanoma ...f Executive Officer. "We believe that the study of azixa in this new indication affords EpiCept with an exp...
Other Tags
(Date:7/9/2014)... If you think winning is one of the key ... Winning along with other mental bonuses ranked near the bottom ... one of 11 big fun factors, according to a new ... when it comes to the "fun" factor, very little research ... into this elusive conceptuntil now. , The results of this ...
(Date:7/9/2014)... Medicine at the University of Pennsylvania in collaboration with ... million grant from the National Cancer Institute (NCI) to ... patients with malignant pleural mesothelioma, a rare, aggressive and ... lining of the lungs and is caused almost exclusively ... clinical trial and additional studies looking at the effects ...
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... than watching World Cup highlights, Brian Williams refreshing old ... unfortunate positions on railings. A University of Colorado Cancer ... shows that YouTube also allows researchers, journals, and ... topics of skin cancer and prevention. , "No matter ... of how we communicate around the world," says Chante ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
(Date:7/9/2014)... delivered by Caesarean section have a different intestinal flora than ... why this is the case and what it means for ... Medical Sciences therefore decided to scrutinise the impact of birth ... of newborn mouse pups. , The study ... lower number of cells that strengthen the immune system, says ...
(Date:7/9/2014)... hunts in Indiana state parks have helped restore the ... by overabundant populations of white-tailed deer, a Purdue study ... associate professor of forest ecology, found that a 17-year-long ... in state parks has successfully spurred the regrowth of ... browsing deer. , Jenkins said that while hunting ...
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2Hunting gives deer-damaged forests in state parks a shot at recovery 2USF study: Amphibians can acquire resistance to deadly fungus 2
Other Contents